Timing note: The event date provided is Thursday, August 6, 2026—which is today, not tomorrow. This preview is written ahead of BD’s FY2026 third-quarter report and call.
BD enters Q3 with a constructive fundamental setup but a higher market bar. The company exceeded expectations in Q2, raised full-year adjusted EPS guidance, demonstrated broad strength across its growth platforms, and continued to return capital through buybacks while reducing debt. Meanwhile, the stock closed at $170.69 on August 5, up roughly 17.9% since May 6 and 9.7% since July 6, making a simple in-line report and unchanged outlook less likely to be viewed as a clear catalyst.
The central question is whether BD can show that the underlying portfolio is moving toward its targeted mid-single-digit growth profile despite three known drags—Alaris comparisons, vaccine-delivery demand, and China—while protecting margins from tariffs and other supply-chain costs.
The available pre-earnings market digest indicates expectations of approximately 2.6% FX-neutral revenue growth and $3.14 of adjusted EPS. Those numbers are broadly consistent with management’s prior commentary that second-half revenue growth should resemble first-half growth.
| Metric / issue | What investors should watch |
|---|---|
| FX-neutral revenue growth | Around or above the ~2.6% expected rate, with evidence that the broader portfolio remains near mid-single-digit growth. |
| Adjusted EPS | Approximately $3.14 is the key reference point. |
| FY2026 adjusted EPS guide | BD’s current range is $12.52–$12.72. The midpoint implies a heavily weighted Q4 after first-half adjusted EPS of $5.38. |
| Margins | Confirmation that productivity and mix are offsetting tariff pressure sufficiently to support roughly 25% adjusted operating margin for FY2026. |
| Growth-platform execution | Advanced Patient Monitoring, biologics/GLP-1 delivery, PureWick, Advanced Tissue Regeneration, peripheral vascular and pharmacy automation. |
| Regulatory / quality update | Any update on the El Paso warning letter, ChloraPrep/PurPrep shipping, Alaris remediation, and the Pyxis quality-system warning letter. |
At the midpoint of FY2026 guidance, BD needs roughly $7.24 of adjusted EPS in the second half. If Q3 lands at the $3.14 reference point, implied Q4 adjusted EPS is about $4.10—so commentary supporting the expected fourth-quarter ramp will matter as much as the Q3 print.
BD’s Q2 result supported management’s case that the post-Waters-transaction company is becoming a more focused medtech operator. Q2 revenue grew 2.6% FX-neutral, with management saying more than 90% of the portfolio produced mid-single-digit growth. The reported result was held back by Alaris, China, and vaccine-related demand—areas management characterized collectively as less than 10% of revenue.
For Q3, investors will want confirmation that the favorable parts of the portfolio remain durable:
BioPharma is particularly important this quarter. BD disclosed in July that the segment will report directly to CEO Tom Polen after the October retirement of Mike Garrison, emphasizing its strategic importance. Investors should look for proof that accelerating biologics and GLP-1 exposure can overcome vaccine weakness and move the segment back to sustained growth.
In Q2, adjusted gross margin declined 90 bps and adjusted operating margin declined 110 bps year over year. Tariffs represented a 160-bp headwind, partly offset by productivity and mix. BD nevertheless delivered results above its own expectations.
That makes the Q3 margin bridge critical:
A reaffirmed 25% adjusted operating-margin target would be constructive. A guide reduction tied to tariffs, resin/oil costs, or incremental remediation spending would likely outweigh an otherwise solid revenue result.
BD reported Alaris share gains in Q2 and said it had the largest competitive funnel in the business’s history. The problem is not underlying competitiveness; it is the comparison against a large remediation-driven upgrade cycle.
Management has been explicit: Alaris is a roughly 100-bp FY2026 growth headwind, expected to become a 200-bp FY2027 headwind before stabilizing thereafter. Investors should therefore focus on share gains, consumables pull-through, and the pace of remediation rather than expecting Alaris to drive near-term reported growth.
China volume-based procurement and related market dynamics remain a drag across Medical Essentials and Interventional. In BioPharma, sharply lower vaccine demand is offsetting the strong GLP-1 and biologics story. A better-than-expected Q3 would likely require either less pressure in these areas or stronger growth elsewhere.
The Q2 10-Q disclosed an FDA warning letter at BD’s El Paso facility involving ChloraPrep and PurPrep products. BD had voluntarily placed those products on U.S. shipping hold while conducting additional release testing. Management’s Q3 update should clarify whether shipments have normalized, whether costs or lost sales were material, and whether corrective actions could create a longer-tail earnings risk.
The ongoing Alaris consent decree, the Pyxis/dispensing warning letter, product-remediation costs, and sterilization regulation also remain important—not necessarily near-term thesis breakers, but material quality-of-earnings considerations.
BD’s Q2 capital actions were aggressive: it completed a $2.0 billion accelerated share repurchase, repurchased approximately $2.25 billion of stock year to date, and retired roughly $2.1 billion of debt during the quarter. Net leverage finished Q2 near 2.9x, versus a long-term target of 2.5x.
For the call, investors should assess:
Bullish outcome - FX-neutral growth above ~2.6%, led by Interventional and Connected Care; - BioPharma performs better than expected, with biologics/GLP-1 strength increasingly offsetting vaccines; - Margin performance demonstrates tariff mitigation and productivity leverage; - FY2026 guide is raised or at least reinforced with greater confidence; - No incremental El Paso, Alaris, or Pyxis regulatory concern.
In-line outcome - Growth remains in the 2–3% FX-neutral range; - EPS meets the ~$3.14 reference point; - FY2026 guidance is reiterated; - Management maintains confidence in a Q4 earnings ramp but offers limited new catalyst.
Bearish outcome - Growth misses because of softer BioPharma, China, or hospital capital spending; - Tariff, freight, resin, or remediation costs pressure margins; - The full-year EPS range is narrowed or cut; - Regulatory commentary suggests the El Paso warning letter or other quality matters will have a more durable financial impact.
BD has improved its setup since Q2: the core portfolio is growing faster than the headline rate, higher-growth platforms are gaining weight, productivity is real, and capital returns are meaningful. But with the stock already up sharply into earnings, investors likely need evidence of broad organic acceleration, tariff-resilient margins, and confidence in the second-half guide to support another leg higher.
The two most important call questions are straightforward: Can BioPharma inflect as GLP-1/biologics scale, and can BD sustain margin expansion while absorbing tariffs and managing regulatory obligations?